Production (Stage)
Drugs Made In America Acquisition Corp.
DMAA
$10.18
-$0.01-0.10%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Net Income | 548.20% | ||||
| Total Depreciation and Amortization | -- | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | -4,818.04% | ||||
| Change in Net Operating Assets | -111.91% | ||||
| Cash from Operations | -103.90% | ||||
| Capital Expenditure | -- | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -- | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | 12.53% | ||||
| Issuance of Common Stock | 929,090.40% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 101.23% | ||||
| Cash from Financing | 187,420.91% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -300.00% | ||||